RISK OF HBV REACTIVATION DURING THERAPIES FOR HCC: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/t0qwb657Keywords:
HBV reactivation, Hepatocellular carcinoma (HCC), Hepatitis B virus (HBV)Abstract
Background: Hepatitis B virus (HBV) reactivation in the setting of immunosuppressive therapy, and in particular chemotherapy, has garnered increasing attention because reactivation can lead to hepatitis, liver failure, and death and also interrupt or delay treatment. The risk of reactivation depends on HBV serological status and the intensity of chemotherapy regimens. HBV reactivation can occur in hepatocellular carcinoma
(HCC) treatment such as transarterial chemoemblization (TACE), resection, and radiofrequency ablation (RFA).
The aim: This study aims to explain the risk of HBV reactivation during therapies for HCC
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study can show that it meets all requirements. So, experts can ensure that the research is up to date. For this search approach, publications that came out between 2013 and 2023 are taken into account. Several different online reference sources were used to conduct this study. It was decided not to take into account cut reviews, works that have already been published, or works that are only half finished.
Result: On the PubMed database, our search results returned 49 articles, while our search results on Sage journal returned 105 articles. Search results conducted since 2013 yielded a total of 34 articles for PubMed and 80 articles for Sage journal. In the end, we compiled a total of 7 articles. We list five eligible studies.
Conclusion: HBV reactivation occurs after the curative resection of HBV-related HCC in patients with low hepatitis B viral loads. Postoperative HBV reactivation was related to the recurrence of HBV-related HCC. Use of antiviral therapy and close monitoring of viral loads may be helpful to reduce the recurrence of HBV-related HCC after resection.
References
Sohn W, Paik YH, Cho JY, Ahn JM, Choi GS, Kim JM, et al. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat. 2015;22(6):539–50.
Teng CF, Wu HC, Shyu WC, Jeng L Bin, Su IJ. Pre-s2 mutant-induced mammalian target of rapamycin signal pathways as potential therapeutic targets for hepatitis B virus-associated hepatocellular carcinoma. Cell Transplant. 2017;26(3):429–38.
Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy. Antivir Ther. 2019;24(2):105–15.
Jun BG, Kim YD, Kim SG, Kim YS, Jeong SW, Jang JY, et al. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study. PLoS One. 2018;13(7):1–10.
Xia Z, Zhang J, Chen W, Zhou H, Du D, Zhu K, et al. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Infect Dis Poverty. 2023;12(1):1–20.
Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol. 2021;13:1– 20.
Li P, Zhou L, Ye S, Zhang W, Wang J, Tang X, et al. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis. Front Immunol. 2021;12(July):1–8.
Lin H, Wu H, Cong N, Liu B, Liu C, Han D. Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma. Technol Cancer Res Treat. 2020;19:1– 6.
Zhao Q, Xu X, Yue J, Zhu K, Feng R, Jiang S, et al. Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma. Therap Adv Gastroenterol. 2017;10(2):231–41.
Spaan M, Bruce M, Agarwal K, Carey I. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C. Antivir Ther. 2018;23:539–42.
Yin S, Zhang F, Wu J, Lin T, Wang X. Incidence, risk factors, and clinical outcomes of HBV reactivation in nonliver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis. PLoS
Med [Internet] 2023;20(3 March):1–20. Available from: http://dx.doi.org/10.1371/journal.pmed.1004196
Li Z, Dong Y, Fan M, Yin Y, Zhu J, Li B, et al. Analysis of Hepatitis B Virus Reactivation After Radiotherapy in Patients With Hepatocellular Carcinoma Using the Lyman NTCP Model. Technol Cancer Res Treat. 2019;18:1–9.
Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133(2):137–46.
Tang W, Chen L, Zheng R, Pan L, Gao J, Ye X, et al. Prophylactic effect of lamivudine for chemotherapy-induced hepatitis B reactivation in breast cancer: A meta-analysis. PLoS One. 2015;10(6):1–12.
Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol. 2018;24(28):3181–91.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
